Live Feeds
● LIVE Updated 21h ago · 29 sources tracked

New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many

Daraxonrasib, also known as Rasonque, is showing promise in early trials for treating lung cancer in addition to its recent approval for metastatic pancreatic cancer. Furthermore, the Food and Drug Administration has granted Breakthrough Therapy Designation to daraxonrasib combined with chemotherapy for first-line metastatic pancreatic cancer. Patients dealing with metastatic pancreatic adenocarcinoma have faced insurance hurdles and weeks of waiting to access the daily oral multi-selective RAS(ON) inhibitor following its initial regulatory approval from Revolution Medicines.

RSS Source map (29)

What changed

The Food and Drug Administration granted Breakthrough Therapy Designation to daraxonrasib plus chemotherapy for first-line metastatic pancreatic cancer, while early trials show the drug may also help fight treatment-resistant lung cancer.

Live updates

  1. Daraxonrasib Shows Promise in Lung Cancer and Wins FDA Designation

    Daraxonrasib, also known as Rasonque, is showing promise in early trials for treating lung cancer in addition to its recent approval for metastatic pancreatic cancer. And the Food and Drug Administration has granted Breakthrough Therapy Designation to daraxonrasib combined with chemotherapy for first-line metastatic pancreatic cancer. Patients dealing with metastatic pancreatic adenocarcinoma have faced insurance hurdles and weeks of waiting to access the daily oral multi-selective RAS(ON) inhibitor following its initial regulatory approval from Revolution Medicines.

    Why it matters

    The expansion of daraxonrasib into early lung cancer trials and its new breakthrough designation signify broader therapeutic potential for a medication originally targeted at pancreatic tumors. Access remains a critical issue as administrative barriers delay patient treatment despite ongoing regulatory advancements.

    What is confirmed

    • Daraxonrasib (Rasonque) is showing promise in the treatment of lung cancer in early trials.
    • The FDA granted Breakthrough Therapy Designation to daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer.

    What to watch next

    • Whether insurance coverage timelines improve for patients prescribed daraxonrasib.
    • Further clinical trial results regarding daraxonrasib and treatment-resistant lung cancer.
    Sources used for this update (8)
    1. jen.jiji.com — Lorena Isceri, crowd at the funeral in Squinzano: "Here to take a piece of this family's pain"
    2. jen.jiji.com — Five thousand dollars for every American? The 'Trump dividends' would cost over a trillion
    3. jen.jiji.com — Ukraine, bombs on Kyiv: 2 injured. Russian raid on shopping center: death toll rises to 5
    4. www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
    5. finance.biggo.com — Andrew Huberman: The MDMA Therapy Setback Wasn't the Drug — It Was the Wild West Around It
    6. oncodaily.com — FDA Grants Breakthrough Therapy Designation to Daraxonrasib Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer
    7. jen.jiji.com — Bonino, today State funeral in Rome: Mattarella and Meloni present
    8. jen.jiji.com — America's Cup, Sport e Salute welcomes a Luna Rossa delegation in Rome
    confidence 100%

  2. Insurance Delays Affect Access to New Pancreatic Cancer Drug Rasonque

    Patients are struggling to access Rasonque, a pancreatic cancer drug from Revolution Medicines, despite its FDA approval. While the medication provides a targeted alternative to general chemotherapy, insurance coverage is taking weeks to catch up with the regulatory approval. This gap creates a barrier for adults with metastatic pancreatic adenocarcinoma who require the daily oral multi-selective RAS(ON) inhibitor to treat specific genetic mutations.

    Why it matters

    The FDA previously approved daraxonrasib to move oncology toward personalized medicine. This shift mirrors the use of mRNA vaccines for melanoma. Current research aims to overcome KRAS resistance to improve long-term patient outcomes.

    What is confirmed

    • The FDA approved a daily oral multi-selective RAS(ON) inhibitor for adults with metastatic pancreatic adenocarcinoma.
    • Rasonque is a pancreatic cancer drug developed by Revolution Medicines.

    Still unconfirmed

    • Insurance coverage for Rasonque can take weeks to catch up after FDA approval.

    What to watch next

    • Updates on insurance provider reimbursement policies for Rasonque
    • Clinical data on overcoming KRAS resistance to improve long-term effectiveness
    Sources used for this update (5)
    1. www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
    2. jen.jiji.com — Raffaella Fico: "I was betrayed, I immediately kicked him out of the house. Let's stop blaming women"
    3. jen.jiji.com — Early breast cancer: over 30,000 genomic tests prescribed in Italy in 5 years
    4. jen.jiji.com — Wave of bad weather over Italy: orange and yellow weather alert for thunderstorms on Thursday, September 10
    5. www.sfexaminer.com — Campaign cash plummets as Supervisor Alan Wong heads for likely full term
    confidence 90%

  3. FDA Approves Daily Pill for Pancreatic Cancer Treatment

    The FDA approved daraxonrasib, a daily oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This drug targets specific genetic mutations, moving treatment away from general chemotherapy toward personalized oncology. Current medical research now focuses on overcoming KRAS resistance to increase the long-term effectiveness of the treatment. This approval mirrors recent advancements in personalized medicine, such as mRNA cancer vaccines used for melanoma.

    Why it matters

    Pancreatic adenocarcinoma is traditionally a deadly disease with limited targeted options. The shift toward genetic-specific inhibitors allows doctors to treat the molecular drivers of a tumor. This approach aims to improve patient outcomes by reducing the reliance on broad-spectrum chemotherapy.

    What is confirmed

    • The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
    • Daraxonrasib is an oral multi-selective RAS(ON) inhibitor.
    • The drug is administered as a daily pill.

    What to watch next

    • Research data regarding the success of overcoming KRAS resistance
    • FDA approval of additional RAS inhibitors for other cancer types
    Sources used for this update (5)
    1. www.dailymail.com — I developed a hidden health problem at 13 that's affecting ever more girls. It left me exhausted, ashamed and struggling with intimacy... we must talk about it before mo…
    2. www.sfexaminer.com — Tech workers start to see promise in unions
    3. www.sandiegouniontribune.com — San Diego Union-Tribune
    4. www.yahoo.com — FDA approves new drug for pancreatic cancer. Who’s eligible and how does it work?
    5. www.sfexaminer.com — A tidier Rivian (in size and price) is ready for the suburbs
    confidence 100%

  4. FDA-Approved Daraxonrasib Joins Shift Toward Personalized Pancreatic Cancer Care

    The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a transition toward personalized oncology, mirroring recent progress in mRNA cancer vaccines for melanoma. While daraxonrasib provides a new option for a traditionally deadly disease, current research is now focusing on overcoming KRAS resistance to improve long-term efficacy. These developments indicate a broader trend of targeting specific genetic mutations to treat aggressive cancers rather than relying on generalized chemotherapy.

    Why it matters

    Pancreatic adenocarcinoma is historically difficult to treat with high mortality rates. The emergence of RAS(ON) inhibitors and mRNA technology represents a move toward precision medicine. Researchers are now investigating how to prevent tumors from developing resistance to these targeted therapies.

    What is confirmed

    • The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma.
    • Moderna and Merck developed a personalized mRNA cancer vaccine that prevented melanoma recurrence in late-stage trials.

    Still unconfirmed

    • Susanna Fletcher Greer is researching methods to unlock KRAS resistance.

    What to watch next

    • Clinical trial results for KRAS resistance inhibitors
    • Long-term survival data for patients using daraxonrasib
    Sources used for this update (7)
    1. jen.jiji.com — America's Cup, Frecciarossa official sponsor of Luna Rossa
    2. jen.jiji.com — US Open, today Musetti-Sweeny - Live
    3. jen.jiji.com — Kills wife and 14-year-old son then commits suicide in Finale Ligure, alarm raised by employer and the note: what we know
    4. jen.jiji.com — Vicenzaoro, Peraboni (leg): "We are a point of reference even in a time of crisis"
    5. www.dailymail.com — Cassandra Thorburn takes a swipe at her ex-husband Karl Stefanovic as she reveals he did not reach out after her cancer diagnosis: 'I know who he is'
    6. www.dailymail.com — Bella Hadid poses in wet T-shirt and underwear as she lies in river for sizzling new snaps
    7. oncodaily.com — Susanna Fletcher Greer: Two Hits, One Target – Unlocking KRAS Resistance
    confidence 90%

  5. FDA Approves Daraxonrasib for Pancreatic Cancer

    The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma, marking a shift toward personalized cancer treatments. This development follows a similar breakthrough by Moderna and Merck, whose personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. These advancements offer new options for diseases traditionally considered deadly.

    Why it matters

    The approval of daraxonrasib and the success of Moderna and Merck's cancer vaccine represent significant progress in the fight against cancer. Pancreatic adenocarcinoma is a particularly challenging disease, and new treatments are urgently needed. The use of targeted inhibitors and vaccines to customize patient care is a promising approach. This trend is expected to continue, with more personalized treatments emerging in the future.

    What is confirmed

    • The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma.
    • Moderna and Merck's personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials.

    Still unconfirmed

    • Pressure grows among Republicans for Trump to deploy Maga Inc.'s substantial financial resources to support party candidates.

    What to watch next

    • Further FDA approvals of personalized cancer treatments
    • Results from ongoing trials of Moderna and Merck's cancer vaccine
    • Development of new targeted inhibitors and vaccines for pancreatic adenocarcinoma
    Sources used for this update (5)
    1. www.fox5dc.com — FOX 5 DC | Local News, Weather, and Live Streams | WTTG
    2. www.theglobeandmail.com — Globe Investor
    3. www.nfl.com — NFL NEWS
    4. jen.jiji.com — Trump hosts at White House Republicans on the fence, pressing on 400 mln
    5. finance.biggo.com — Moderna CEO Stéphane Bancel: The Algorithm Behind Our Cancer Vaccine Will Only Get Better
    confidence 90%

  6. FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma

    The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a shift toward personalized cancer treatments that train the immune system to target specific patient cancers. This development follows a similar breakthrough by Moderna and Merck, whose personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. These combined advancements offer new options for diseases traditionally considered deadly by utilizing targeted inhibitors and vaccines to customize patient care.

    Why it matters

    Pancreatic cancer is traditionally difficult to treat with high mortality rates. The move toward personalized medicine allows for therapies tailored to a patient's specific genetic markers.

    What to watch next

    • Clinical data on daraxonrasib long-term efficacy
    • FDA approval of further personalized mRNA vaccines
    Sources used for this update (7)
    1. omaha.com — HazToGo Fall Mobile Events Offer Free, Convenient Disposal
    2. journalstar.com — Men turn to cosmetic clinics to complete transformation after GLP-1 weight-loss drugs
    3. jen.jiji.com — US Open, today Musetti-Fery: schedule, head-to-head and where to watch it on TV
    4. finance.yahoo.com — MassLive’s Most Influential Innovators of 2026
    5. jen.jiji.com — USA, Bank of America Vice President is the woman stabbed to death in Times Square
    6. jen.jiji.com — Inter, Ausilio will not renew contract: leaves club after 28 years
    7. jen.jiji.com — Rome, fire in a garage on via Vitellia: electric car involved, 6 intoxicated
    confidence 100%

  7. FDA-Approved Pancreatic Cancer Drug Joins New Wave of Personalized Oncology

    The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval coincides with a broader shift toward personalized cancer treatment, highlighted by a breakthrough from Moderna and Merck. Their personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. Experts describe these developments as the start of an era where vaccines and targeted inhibitors train the immune system to fight a specific patient's cancer, offering new options for diseases traditionally considered deadly.

    Why it matters

    Pancreatic adenocarcinoma is notoriously difficult to treat and often fatal. The introduction of daraxonrasib provides a new chemical approach to inhibition, while mRNA technology introduces a custom-made immunological approach. Together, these represent a transition from general chemotherapy to patient-specific precision medicine.

    What is confirmed

    • The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
    • Moderna and Merck developed a personalized mRNA cancer vaccine that prevents melanoma recurrence in late-stage trials.

    What to watch next

    • Clinical trial results for mRNA vaccines targeting pancreatic cancer
    • Long-term survival data for patients using daraxonrasib
    Sources used for this update (9)
    1. www.straitstimes.com — Success after a century of failures: Inside Moderna and Merck’s cancer vaccine breakthrough
    2. journalstar.com — Dolly Parton’s immortal music legacy in 10 essential songs
    3. jen.jiji.com — Germany, knife attack at Rosenheim station: 31-year-old British woman killed
    4. jen.jiji.com — US Open, Paolini - Erjavec in the first round: live match
    5. tucson.com — Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
    6. journalstar.com — DC’s interstellar peacekeepers have landed in Nebraska — here’s where and why
    7. jen.jiji.com — Nepal authorities, ‘risk of new floods, at least 800 dead and over 3,000 missing’
    8. jen.jiji.com — Ranucci Case, Report journalists' assembly: "State of agitation, we will strike if necessary"
    9. www.applevalleynewsnow.com — Week in review: Test your knowledge of notable news
    confidence 100%

  8. FDA Approves New Drug for Pancreatic Cancer

    The US FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a new approach to treating the disease, which is notoriously deadly. Some patients, including former University of Florida President Sasse, have already received the medication, crediting it with extending their life.

    Why it matters

    Pancreatic cancer has limited treatment options and poor survival rates. The approval of daraxonrasib offers hope for improved treatment outcomes. This development is part of a larger effort to develop effective treatments for pancreatic cancer.

    What is confirmed

    • The FDA approved a pill from Revolution Medicines to treat pancreatic cancer.
    • The approved drug is designed to improve survival rates for pancreatic cancer.
    • Some patients at Dartmouth are among the first to receive the medication.
    • Former University of Florida President Sasse credited the drug with extending his life.
    • The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

    What to watch next

    • Further clinical trials to confirm the efficacy of daraxonrasib
    • Development of similar medicines by other pharmaceutical companies
    • Long-term effects of daraxonrasib on patients with pancreatic cancer
    Sources used for this update (7)
    1. medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
    2. jen.jiji.com — Report, Presutti and Piervincenzi to host. Three relocation proposals for Ranucci
    3. jen.jiji.com — Roller coaster at Six Flags park in California closes: "Linked to brain injuries, coma, and deaths"
    4. journalrecord.com — After a century of failures, cancer vaccine hits major milestone
    5. jen.jiji.com — Ukraine, Russian raid against warehouse near Kyiv causes massacre: at least 27 dead
    6. www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
    7. jen.jiji.com — Return migration, Codacons: "Chaos between construction sites and expensive fuel, odyssey for motorists"
    confidence 90%

  9. FDA Approves First-of-a-Kind Pancreatic Cancer Pill from Revolution Medicines

    The Food and Drug Administration approved a first-of-a-kind pill from Revolution Medicines on Wednesday to treat pancreatic cancer. The drug is designed to improve survival rates for a disease noted for being notoriously deadly. Some patients at Dartmouth are among the first to receive the medication. Former University of Florida President Sasse credited the drug with extending his life. This approval marks a new approach to treating the disease and has sparked a race to develop similar medicines.

    Why it matters

    Pancreatic cancer is traditionally difficult to treat with high mortality rates. This approval introduces a new class of medication that experts believe will transform standard care. The development positions Revolution Medicines as a potential major player in oncology.

    What is confirmed

    • The FDA approved a new drug for pancreatic cancer on Wednesday.
    • Revolution Medicines developed the first-of-a-kind pill for the disease.
    • The drug is intended to improve survival for patients with pancreatic cancer.

    Still unconfirmed

    • The drug is named Rasonque.
    • Revolution Medicines could become the next oncology titan.

    What to watch next

    • FDA approval of subsequent medicines following this new treatment model.
    Sources used for this update (10)
    1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
    2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
    3. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
    4. WMUR — Dartmouth patients among first to get new drug that fights pancreatic cancer
    5. www.forbes.com — Forbes Daily: Nvidia Beats Expectations As Data Center Business Grows
    6. BioSpace — RevMed could become ‘next oncology titan’ with Rasonque nod
    7. www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
    8. www.statnews.com — Decoding DEA action on kratom-related substances
    9. www.usatoday.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
    10. www.kpbs.org — FDA approves landmark pancreatic cancer drug that's shown to improve survival
    confidence 90%